Podcasts about pleural

Pleural space disease is a really common cause of respiratory distress in many of our patients, from traumatic pneumothorax patients to pyothorax cats and everything in between. And it's also a very nursing-heavy disease, with many ways we can use our skills to better care for these challenging patients. In this episode (the first in a mini-series on pleural space disease), we'll look at what the pleural space is, why it should be there, and what happens when things end up there when they shouldn't. We'll touch on the common causes, the signs to look out for, and the diagnostic, treatment, and nursing care needs these patients have, so that you can make more of a difference to them in practice. --- Resources mentioned in this episode:

Dr Shaheen Shahid, Respiratory Registrar at Royal Derby Hospital, shares a comprehensive summary of management of malignant pleural effusions as per BTS guidelines.We recommend considering listening to the following other podcast episodes to supplement this episode:Episode 19 - Pleural EffusionPodomatic Apple Podcasts SpotifyEpisode 34 - PneumothoraxPodomatic Apple Podcasts Spotify Episode 133 - Pleural InfectionPodomatic Apple Podcasts SpotifyEpisode 162 - Chest DrainPodomatic Apple Podcasts SpotifyFollow us on Instagram!Join our Discord server or follow our podcast via our Linktree!

Episode 69 - Updates in Pleural Disease Research by AABIP

Professor Gary Lee established the first dedicated pleural service in the southern hemisphere in 2009, at the Sir Charles Gairdner Hospital in Perth. He says that pleural disease has finally come to be regarded as an area of subspeciality interest in its own right, not just a complication of other comorbidities. In this podcast he presents a potted history of key developments in the management of pleural effusion in particular. This is diagnosed in about 60,000 people every year in Australia, mainly as a result of infection or malignancy. With mentors in the UK, Professor Lee conducted some of the earliest trials on fibrinolytics and DNAses to break down purulent effusions. They also put to the test protocols for pleurodesis via talcum insufflation that date back to the 1930s. Professor Lee's more recent clinical research has focused on the use of indwelling pleural catheters that a patient can use to drain pleural effusate when feeling breathless. He has also a made an important contribution to conservative management guidelines for primary spontaneous pneumothorax. This story is great example of how clinical practice emerges imperfectly from a soup of evidence, accidents, human biases and system. Guest Prof Gary Lee PhD FRACP FRCP FCCP (Pleural Service, Sir Charles Gairdner Hospital in Perth; University of Western Australia).Co-hostDr Marion Leighton FRACP (Wellington Hospital).ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘Reconstruct' by Amaranth Cove, ‘Nagba Algooah' by Ebo Krdum. ‘Vittoro' by Borrtex provided courtesy of FreeMusicArchive. Image by ilbusca licenced through Getty Images.   Editorial feedback kindly provided by RACP physicians Aidan Tan, Maansi Arora, Simeon Wong, Hugh Murray and Vanessa Wong.Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

Don't miss our Travel Nurse Bootcamp Webinar, happening every Wednesday at 7 PM EST. Sign up at https://ReMarNurse.com/jobs Join us with the #1 Instructor on the planet Professor Regina M. Callion MSN, RN as we discuss the NCLEX teaching points on the subject of Pleural Effusion, a condition characterized by the accumulation of excess fluid in the pleural space surrounding the lungs. Learn about its meaning and importance, the different types such as transudative and exudative, and explore the common causes including heart failure and infections. Discover the key symptoms like shortness of breath and chest pain, and understand how healthcare professionals diagnose this condition using imaging studies and thoracentesis. We'll also discuss various treatment options from medications to surgical interventions, along with essential nursing interventions for effective patient care. Don't forget to like, comment, and subscribe for more informative content on nursing and healthcare topics. Download the ReMar V2 App: ►For iOS: https://apps.apple.com/us/app/remar-v2/id6468063785 ►For Android: https://play.google.com/store/apps/details... ► Find JOBS: http://ReMarNurse.com/jobs ► NCLEX for Africa - http://ReMarNurse.com/KENYA ► Get NCLEX V2: http://www.ReMarNurse.com ►NCLEX V2 Free Trial - http://ReMarNurse.com/free ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/ ► Subscribe Now on YouTube - http://bit.ly/ReMar-Subscription

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics including surgery, immunotherapy, chemotherapy, pathology, and germline testing. Dr. Kindler describes the impact of this guideline and the need for ongoing research in the field. Read the full guideline update, “Treatment of Pleural Mesothelioma: ASCO Guideline Update” at www.asco.org/thoracic-cancer-guidelines.   TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02425 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Hedy Kindler from the University of Chicago, lead author on “Treatment of Pleural Mesothelioma: ASCO Guideline Update.” Thank you for being here today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines in ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Kindler, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this podcast episode, first, Dr. Kindler, can you provide an overview of the purpose and scope of this guideline update on pleural mesothelioma? Dr. Hedy Kindler: The initial ASCO practice guideline on mesothelioma, which we published in 2018, was quite comprehensive, but since that time incredible progress has been made which has truly transformed the management of this disease. So we felt it was really important to update the guideline now, focusing on four key areas: the role of surgery, new systemic treatments, pathologic insights, and germline testing. Brittany Harvey: Great. Thank you for highlighting those key areas of the guideline. And so I'd like to next review the key updated recommendations for our listeners. So starting with what are the new updates for surgery? Dr. Hedy Kindler: So surgery has always been controversial in meso, with significant geographic variation in its use. Now, it's even more controversial. Recent randomized data from the MARS 2 trial, placed in the context of other data we also reviewed in this update, suggest that surgical cytoreduction should not be routinely offered to all patients based solely on anatomic resectability. Surgery should only be offered to highly selected patients with favorable prognostic characteristics. This includes comprehensively staged patients with early-stage epithelioid tumors. Patients should preferably be treated at centers of excellence which have documented low morbidity and mortality, and this should also be done in the context of multimodality therapy and preferably within clinical trials. Brittany Harvey: Understood. I appreciate you reviewing those recommendations for who surgery should be offered to. So following those, what are the main recommendations for immunotherapy for treating pleural mesothelioma? Dr. Hedy Kindler: So for a disease in which for 16 years there was only one FDA-approved regimen, pemetrexed and platinum, the pace of recent changes in systemic therapy has been a welcome change with the FDA approval of doublet immunotherapy in October of 2020 and the approval of chemo immunotherapy just a few months ago in September of 2024. Now that we have choices, we've tried to help clinicians determine the optimal treatment regimen for the individual patient. Doublet immunotherapy with ipilimumab and nivolumab should be offered as a first-line systemic option to any mesothelioma patient. For patients with non-epithelioid histology, doublet immunotherapy is hands down the recommended regimen based on the dramatic improvement in survival from 8.8 to 18.1 months for immunotherapy compared with chemo. For patients with previously untreated epithelioid mesothelioma, either ipilimumab-nivolumab immunotherapy or platinum-pemetrexed chemotherapy are reasonable options. Therapy can be individualized based on the patient's comorbidities, acceptance of differing toxicities. and treatment goals. Chemoimmunotherapy with pembrolizumab, pemetrexed, and carboplatin is a newer treatment option for patients with newly diagnosed pleural mesothelioma. This regimen is noteworthy for its very high objective response rate of 62%. Brittany Harvey: It's great to have those new options to improve outcomes for patients. Beyond the chemoimmunotherapy recommendation that you just described, what are the highlights for chemotherapy recommendations? Dr. Hedy Kindler: So pemetrexed platinum-based chemotherapy with or without bevacizumab still plays a role in this disease and should be offered as a first-line treatment option in patients with epithelioid histology. This regimen is not recommended in patients with non-epithelioid disease unless they have medical contraindications to immunotherapy. Pemetrexed maintenance chemotherapy following pemetrexed-platinum chemotherapy is not recommended. Brittany Harvey: Thank you for reviewing those recommendations as well. So then next, what are the important changes regarding pathology? Dr. Hedy Kindler: Well, one fun fact is that we've changed the name of the disease. It's no longer malignant mesothelioma. Now it's just mesothelioma. Since the non-malignant mesothelial entities have been renamed, all mesos are now considered malignant, so there's no need to use the prefix malignant in the disease name. Mesothelioma should be reported as epithelioid, sarcomatoid, or biphasic because these subtypes have a clear prognostic and predictive value. Knowing the subtype helps us decide on whether chemotherapy or immunotherapy is the optimal treatment for a patient, so it must be reported. Additionally, within the epithelioid subtype, histologic features, including nuclear grade, some cytologic features, and architectural patterns should be reported by pathology because they have prognostic significance. Pathologists have recently identified a premalignant entity, mesothelioma in situ, which can be found in patients with long standing pleural effusions and should be considered in the differential diagnosis. In the appropriate clinical setting, additional testing, including BAP1 and MTAP IHC should be performed. Brittany Harvey: Definitely. These pathologic recommendations are important for treatment selection. So in that same vein, in the final section of the recommendations, what are the updated recommendations from the panel regarding germline testing? Dr. Hedy Kindler: This is one of our most important recommendations, that universal germline testing should be offered to all mesothelioma patients. The proportion of patients with mesothelioma who have pathogenic or likely pathogenic germline variants is similar to other diseases in which universal germline genetic testing and counseling are now the standard of care. This is most commonly observed in the tumor suppressor gene BAP1 and this not only affects cancer risk in patients and their family members, but also has key prognostic significance. For example, pleural mesothelioma patients with BAP1 germline mutations who receive platinum-based chemotherapy live significantly longer, 7.9 years compared to 2.4 years for those without these mutations. Thus, we recommend that all patients with mesothelioma should be offered universal germline genetic counseling and/or germline testing. Brittany Harvey: So there were a large amount of new and updated recommendations in this update. So in your view Dr. Kindler, what is the both importance of this update and how will it impact both clinicians and patients with pleural mesothelioma? Dr. Hedy Kindler: Even as we were researching and writing this update, new data kept emerging which we needed to include. So it's clearly a time of great progress in the management of this disease. We've comprehensively reviewed and analyzed the extensive emerging data and provided clinicians with a roadmap for how to incorporate these new advances into their management of this disease. Brittany Harvey: Absolutely, that is key for optimal patient care. So you've just mentioned emerging data and rapid evidence generation, so what future research developments are being monitored for changes in the treatment of pleural mesothelioma? Dr. Hedy Kindler: Despite these recent advances in disease management, mesothelioma continues to be a lethal cancer, and there's clearly a need to develop better treatments. This includes ongoing studies of novel immunotherapeutic agents such as bispecific antibodies, cell therapy using chimeric antigen receptors targeting mesothelioma tumor antigens, and precision medicine approaches to target tumor suppressor genes. Finally, strategies for early cancer detection and prevention are vital for individuals predisposed to develop mesothelioma due to BAP1 and other germline mutations, as well as for those who are occupationally or environmentally exposed to asbestos. Brittany Harvey: Absolutely. We'll look forward to these new updates to continue development in the field. So thank you so much for this mountain of work to update this guideline, and thank you for your time today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. It's been a pleasure. Thank you for asking me to do this. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline update, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.

Up next for our curriculum series is an episode on Pulmonology! Take a listen so that you're prepared for our pre-test! Author: Dr. Akshita Sahi, PGY-3, UCONN  Host and Editor: Dr. Ritika Kompella, Chief Medical Resident, UCONN Guest speakers: Pulmonary Hypertension: Dr. Jose Soriano, Assistant Professor of Medicine Diffuse parenchymal disease: Dr. Ameer Rasheed, Assistant Professor of Medicine (*correction 8:03: secondary pulmonary lobule, instead of nodule) Pleural disease and pulmonary nodules: Dr. Omar Ibrahim, Associate Professor of Medicine, Director, Interventional Pulmonary Additional resources: https://www.ahajournals.org/doi/10.1161/JAHA.122.029024 https://pubmed.ncbi.nlm.nih.gov/35412560/

Join Brig (Dr) J Muthukrishnan in this engaging episode of our medical podcast as he hosts Lt Col (Dr) Kislay Kishore, an eminent pulmonologist from the Army Institute of Cardiothoracic Sciences, to discuss pleural effusion. Dive into the causes, symptoms, and diagnostic challenges of this common yet complex condition. Lt Col (Dr) Kishore shares his extensive clinical experience, providing valuable insights into identifying and understanding pleural effusion.

On this episode - part 2/2 if you will - we continue our discussion of pleural disease with a focus on hemothorax & management of bronchopleural fistulas. Small tube or large tube? When do you call in the reinforcements? What about endobronchial valves for persistent air leaks? Learn the answers to these questions - and so much more -n with Dr. Mike Sobieszczyk our expert interventionalist! Hosted on Acast. See acast.com/privacy for more information.

In this episode, host Alyssa Watson, DVM, welcomes back Andrew Linklater, DVM, DACVECC, to talk about his recent Clinician's Brief article, “Top 5 Causes of Pleural Effusion in Dogs.” Dr. Linklater reviews what makes an effusion a transudate, exudate, or something in between. He then details his top effusion causes—hemothorax, chylothorax, pyothorax, nonseptic effusion, hydrothorax, and an honorable mention to pneumothorax.Resource:https://www.cliniciansbrief.com/article/pleural-effusions-fluid-lungs-chestContact:podcast@vetmedux.comWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist

On this episode of Critical Care Time, Nick & Cyrus revisit the pleural space! We had SO much great content we opted to split the episode into two parts. We also figured it would be nice to get an interventionalists take on this and we thus recruited Dr. Mike Sobieszczyk to help navigate this complex topic! Here we discuss things like hepatic hydrothorax, indwelling pleural catheters and all things parapneumonic effusion. Check it out and leave us a review! If you missed our first episode on pleural disease, head on back to episode 10 and get caught up. If you like what you heard here, make sure to come back in 2 weeks for the second part! Hosted on Acast. See acast.com/privacy for more information.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pleural Effusion ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Pulmonary section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Sam is joined by Respiratory physician, Dr James Walters on the show this week to discuss your approach to this critical PACES station. ^_^ SUPPORT THE SHOW ^_^> > Sign up for Pastest HERE! <

Professor Eric Lim discusses the outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode our team dives into the diagnosis, workup and management of malignant pleural mesothelioma. Listen as we debate the pros and cons of surgical management of this disease with extrapleural pneumonectomy versus pleural decortication and discuss the nuances of choosing the right approach for the right patient. Learning Objectives - Describe the workup and staging of a patient with malignant pleural mesothelioma - List the subtypes of malignant pleural mesothelioma, characteristics of resectable disease, and patient factors which impact surgical candidacy  - Describe the approach to an extrapleural pneumonectomy and pleural decortication - Analyze which surgical approach is best for various subsets of patients - Describe the adjuvant treatment for malignant pleural mesothelioma Hosts Kelly Daus MD, Adam Bograd MD, Peter White MD, Brian Louie MD Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out more recent episodes: https://app.behindtheknife.org/listen

| 4ª Temporada do Medaholic by Medicamente Academy - Pneumologia | Falemos desta vez de Derrame pleural! Embarca connosco nesta revisão sobre esta patologia, a Ana e o Rafael dão aqui uma ajuda para sistematizar e relembrar o tema! Dêem-nos o vosso feedback e enviem-nos dúvidas e/ou sugestões que tenham. Se ainda não tiveste oportunidade, ouve os episódios anteriores, já disponíveis no Spotify, Apple Podcasts, Google Podcasts e CastBox! Podes acompanhar o projeto na nossa página de Instagram - ⁠⁠⁠⁠⁠⁠⁠@medaholic.podcast⁠⁠⁠⁠⁠⁠⁠ - e entrar em contacto connosco pelo nosso email - ⁠⁠medicamente.academy@gmail.com⁠

  “So much of this is just knowing what is their diagnosis, what medications are they on, what could be the root cause of this—where is their disease to begin with? There's really a lot of differential diagnosis and workup that has to be thought about, you know, when you're dealing with shortness of breath and pulmonary toxicities,” Beth Sandy, MSN, CRNP, OCN®, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about just a few of the pulmonary toxicities oncology nurses may encounter in patients receiving pharmaceutical cancer treatments. This episode is part of a series on cancer symptom management basics; the rest are linked below.  You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), which may be applied to the nursing practice, oncology nursing practice, symptom management, palliative care, supportive care, or treatment.ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by January 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge of pulmonary complications from cancer treatment.   Episode Notes  Complete this evaluation for free NCPD.   Oncology Nursing Podcast Cancer Symptom Management Basics series  ONS Voice articles: Pneumonitis With Immunotherapy Treatment Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding  Clinical Journal of Oncology Nursing articles: Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma Chronic Obstructive Pulmonary Disease: Clinical Implications for Patients With Lung Cancer  Oncology Nursing Forum article: Multifactorial Model of Dyspnea in Patients With Cancer  ONS book: Understanding and Managing Oncologic Emergencies: A Resource for Nurses (third edition)  ONS Symptom Interventions and Guidelines™: Dyspnea  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From Today's Episode  “Your lungs are what is needed to have the gas exchange within your bloodstream. So, when we inhale, we're inhaling oxygen, and we need that gas exchange to occur in the alveoli, which are the tiny, little bubble-like structures within the periphery of the lungs. And they're communicating with tiny, itty-bitty little blood vessels. And that's where the gas exchange occurs, where you get rid of the carbon dioxide from the blood and you get oxygen to the blood. And what ends up happening is there is, for whatever reason it may be, that gas exchange can't occur, and that can result in so many different forms from different toxicities, whether there's an inflammation causing the alveoli not to work correctly, whether there's an obstruction where there's literally something obstructing the air getting into the lungs, or whether there's compression from an external source like a fusion or something like that that is pressing against the lungs where that gas exchange cannot occur.” TS 2:36  “Pulmonary embolism, I'll tell you, is one of the most common things that we see in cancer. As a matter of fact, often patients are diagnosed with cancer because they present with a pulmonary embolism into the E.R. (emergency room) and there's really not a lot of reasons why healthy-otherwise patients develop a PE [pulmonary embolism]. So, we start looking for cancer. So, just having cancer in general puts you in that hypercoagulable state. . . . And then, being on chemotherapy increases that risk.” TS 6:38  “I think we need to really make sure that they're compliant. We need to make sure they're not having bleeding. Are you having significant bruising anywhere? Are you having unprovoked nosebleeds? And by that, I mean, I always tell people, ‘Were you just sitting watching TV and it started dripping?' versus, ‘Oh, I blew my nose and some blood came out.' Okay, well, that is probably pretty common side effect of this and should stop quickly.” TS 12:06  “The problem is the majority of these patients have metastatic disease or an incurable cancer. So, we prefer not to stop it [PE medication] in those patients because if you think about it, their risk comes from the cancer. And we're not getting rid of that if they have metastatic disease. I think for those patients with metastatic disease, as long as they're tolerating it, they're not having bleeding events, we will typically tend to just keep them on it.” TS 13:09  “The main difference with the targeted therapies is it tends to be worse, and it's not something that you can rechallenge. And I think that's kind of one of the most important things to think about here. In immunotherapy, it's like, okay, it's T-cell mediated; we gave you corticosteroids; it calmed itself down. And a lot of times we can rechallenge, and we don't necessarily see it again. Whereas with targeted therapies, you have to be much more cautious. If you look at the package inserts for the EGFR and ALK inhibitors, most of them are going to tell you this is not something you ever rechallenge. Any kind of symptomatic pneumonitis, you're going to permanently discontinue the drug. Because if you give it again, it's going to recur in a pretty bad way, where corticosteroids may not even be helpful again even if you rechallenge them.” TS 17:52  “What can happen in cancer, typically, thoracic cancers—so lung cancer, mesothelioma for sure, thymic cancers like thymomas and thymic carcinomas—often will have pleural effusion or pleural disease as well. But when cancer cells get into that fluid, there's irritation which causes an increase in the amount of fluid there. And then what happens is when that space, that pleural space, is now enlarged with fluid or engorged with fluid, a few things occur here. Patients are short of breath because it's a pressure gradient there. So, you're trying to inhale against this fluid-filled cavity that's making it hard. So, often patients will describe it as it feels like someone's giving you a really tight hug and they won't stop.” TS 21:59  “There is another procedure called a talc pleurodesis, where you can have a procedure where you inject some powder in there that will kind of dry it up. The downside of that is that it kind of fuses the pleura to the lung, so there can be some complications there, some pain, and decreased lung function just from doing that, but it can be an easy fix that you certainly don't want to have an indwelling catheter there.” TS 25:11  “So, patients need to know, if they are short of breath at all, call us; let us know. The other thing that's important is know with their baseline vital signs are, especially their pulse ox. You know, some people, their pulse oximetry may be in the low 90s or upper 80s at baseline. We need to know that because there's a big difference if a patient has, you know, they're living at 99% versus 91% normally. Because if they come in and they live at 99 and they're 91, that's a huge drop. But if they come in and they were 91 to begin with and they're 90, that's not a big difference. So, we really do need to make sure we know what their baseline is before they're starting any treatments.” TS 29:18  “This is not something that you want to downplay. You can't sit there and say, you know, ‘Oh, they smoke a lot, so it's probably that.' Or, ‘They have this type of cancer, so it's probably that.' I think this is something that you have to take shortness of breath seriously, and you have to work up and understand and know your patient. But for the most part, this is not something you're going to just triage to the next day or to a few days later. You're going to need some kind of urgent intervention or workup to be done pretty quickly.” TS 32:54  “I think the biggest misconception is that they can't be treated even if they're severe. Most of these things can be reversed. Part of it is just diagnosing it at first and then going from there and starting the appropriate treatment strategy.” TS 33:29 

REFERENCES: PMID 31315808 PMID 29530870 PMID 29372629 Strange, C. (2023). Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults. Up-To-Date.

Live Nursing Review with Regina MSN, RN! Every Monday & Wednesday we are live. LIKE, FOLLOW, & SUB @ReMarNurse for more.     Save up to 50% off RN & LPN prep this Cyber week only at http://www.ReMarNurse.com   Quick Facts for NCLEX Next Gen Study Guide here - https://bit.ly/QF-NGN Study with Professor Regina MSN, RN every Monday as you prepare for NCLEX Next Gen.   ► Create Free V2 Account - http://www.ReMarNurse.com ► Get Quick Facts Next Gen - https://bit.ly/QF-NGN ► Subscribe Now - http://bit.ly/ReMar-Subscription ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/   ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN. ReMar is the #1 content-based NCLEX review and has helped thousands of repeat testers pass NCLEX with a 99.2% student success rate! ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students to pass boards - fast!

In this two-part episode our team debates management of complex pleural effusions and empyema. Our surgical team is joined by Dr. Jed Gorden, an interventional pulmonologist, as we explore the nuances of deciding on fibrinolytic therapy (part 1) versus surgical management (part 2). Part 1: https://behindtheknife.org/podcast/clinical-challenges-in-thoracic-surgery-complex-pleural-effusions-empyema-part-1-of-2/ Learning Objectives: -Discuss the pros and cons of small bore versus large bore chest tubes for complex pleural effusions  -Review the evidence for fibrinolytic therapy for management of complex pleural effusions -Describe the surgical management of a complex pleural effusion including VATS, open thoracotomy, empyema tube, Eloesser flap, and Clagett window -Create a framework for shared-decision making with patients regarding management of a complex pleural effusion Hosts: Kelly Daus MD, Peter White MD, Jed Gorden, MD and Brian Louie MD Referenced Material https://pubmed.ncbi.nlm.nih.gov/15745977/ Maskell NA, et al. First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 Mar 3;352(9):865-74. doi: 10.1056/NEJMoa042473. Erratum in: N Engl J Med. 2005 May 19;352(20):2146. PMID: 15745977. https://pubmed.ncbi.nlm.nih.gov/21830966/ Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011 Aug 11;365(6):518-26. doi: 10.1056/NEJMoa1012740. PMID: 21830966. https://pubmed.ncbi.nlm.nih.gov/35830586/ Wilshire CL, et al. Comparing Initial Surgery versus Fibrinolytics for Pleural Space Infections: A Retrospective Multicenter Cohort Study. Ann Am Thorac Soc. 2022 Nov;19(11):1827-1833. doi: 10.1513/AnnalsATS.202108-964OC. PMID: 35830586. https://pubmed.ncbi.nlm.nih.gov/37043201/ Wilshire CL, et al. Effect of Intrapleural Fibrinolytic Therapy vs Surgery for Complicated Pleural Infections: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e237799. doi: 10.1001/jamanetworkopen.2023.7799. PMID: 37043201; PMCID: PMC10098968. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out more thoracic surgery episodes here: https://behindtheknife.org/podcast-category/cardiothoracic/

In this two-part episode our team debates management of complex pleural effusions and empyema. Our surgical team is joined by Dr. Jed Gorden, an interventional pulmonologist, as we explore the nuances of deciding on fibrinolytic therapy (part 1) versus surgical management (part 2). Learning Objectives: -Discuss the pros and cons of small bore versus large bore chest tubes for complex pleural effusions  -Review the evidence for fibrinolytic therapy for management of complex pleural effusions -Describe the surgical management of a complex pleural effusion including VATS, open thoracotomy, empyema tube, Eloesser flap, and Clagett window -Create a framework for shared-decision making with patients regarding management of a complex pleural effusion Hosts: Kelly Daus MD, Peter White MD, Jed Gorden, MD and Brian Louie MD Referenced Material https://pubmed.ncbi.nlm.nih.gov/15745977/ Maskell NA, et al. First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 Mar 3;352(9):865-74. doi: 10.1056/NEJMoa042473. Erratum in: N Engl J Med. 2005 May 19;352(20):2146. PMID: 15745977. https://pubmed.ncbi.nlm.nih.gov/21830966/ Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011 Aug 11;365(6):518-26. doi: 10.1056/NEJMoa1012740. PMID: 21830966. https://pubmed.ncbi.nlm.nih.gov/35830586/ Wilshire CL, et al. Comparing Initial Surgery versus Fibrinolytics for Pleural Space Infections: A Retrospective Multicenter Cohort Study. Ann Am Thorac Soc. 2022 Nov;19(11):1827-1833. doi: 10.1513/AnnalsATS.202108-964OC. PMID: 35830586. https://pubmed.ncbi.nlm.nih.gov/37043201/ Wilshire CL, et al. Effect of Intrapleural Fibrinolytic Therapy vs Surgery for Complicated Pleural Infections: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e237799. doi: 10.1001/jamanetworkopen.2023.7799. PMID: 37043201; PMCID: PMC10098968. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out more thoracic surgery episodes here: https://behindtheknife.org/podcast-category/cardiothoracic/

Episode 54 - Probing The BTS Pleural Diseases Guidelines - Najib Rahman (1) by AABIP

Episode 54 - Probing The BTS Pleural Diseases Guidelines - Najib Rahman by AABIP

We're diving back into some pleural fluid today (okay that is kind of gross to think about and we apologize). If you haven't listened to our prior pleural effusion episodes and want to start from the top, then check out … Continue reading →

Pleural effusions are defined as a buildup of excess fluid between the pleura and it can occur as a consequence of a wide variety of conditions. In this episode, you'll learn: The two types of pleural fluid Risk factors for pleural effusion Complications of pleural effusion Signs and symptoms of pleural effusion Priority assessments How pleural effusions are identified and what lab tests are conducted Treatments for pleural effusion Important patient education To review chest tube management, listen to episode 124. To dive deep into respiratory assessment, listen to episode 237. Read the article about pleural effusions and view references here. Grab the FREE Straight A Nursing LATTE template to easily create your own Med Surg study guides. Are you looking for an easier way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics as well as out-of-this-world study guides!     If this episode helped you, please take a moment to rate and review the show! This helps others find the podcast, which helps me help even more people

This episode covers pleural effusions.Written notes can be found at https://zerotofinals.com/medicine/respiratory/pleuraleffusion/ or in the respiratory section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

In this panel episode recorded at SIR 2023, Drs. Stephen Hunt, Chuck Martin, and Gaurav Gadodia update us on current applications and future directions of augmented reality in interventional radiology. --- CHECK OUT OUR SPONSOR Medtronic Ellipsys Vascular Access System https://www.medtronic.com/ellipsys --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/voyqG5 --- SHOW NOTES Dr. Hunt explains the differences between virtual reality (VR), augmented reality (AR), and mixed reality (MR) since there is increasing levels of overlap between virtual and real worlds with each category . He notes that all three are being explored in surgical fields, especially orthopedics and neurosurgery. Within IR, augmented reality can be used to adjust images and subtract out respiratory motion, making biopsies and ablations safer and more effective. Dr. Hunt became interested in AR when his PIGI Lab at the University of Pennsylvania needed 3D models to access liver tumors in experimental mice. Additionally, AR is a useful tool for planning difficult procedures and teaching interventional procedures to trainees across the globe. Dr. Martin speaks about the intersection of medicine and industry. He directs research studies for Mediview, a company focused on bringing AR into medical imaging. Dr. Martin speaks about the important role that industry plays in commercializing an invention and getting it into operators' hands. As larger companies enter the AR space, accessibility and user interfaces will improve. Additionally, the shift towards AR product development can guide future FDA regulations. Dr. Gadodia's engineering background made him excited to enter the AR space as resident at the Cleveland Clinic. He highlights applications of AR in the non-academic setting. Using a headset could increase procedural efficiency and access to care. Finally, we discuss major shifts in industry and medicine that favor the increasing use of AR, such as industry's need for clinician input in product development, the multitude of startups working on the same issues, and the overarching goal of patient safety. --- RESOURCES Ep. 7- Lung Tumor Ablation with Dr. Stephen Hunt: https://www.backtable.com/shows/vi/podcasts/7/lung-tumor-ablation Ep. 53- International IR Volunteer Work with Dr. Stephen Hunt: https://www.backtable.com/shows/vi/podcasts/53/international-ir-volunteer-work Mediview: https://mediview.com/ Microsoft HoloLens: https://www.microsoft.com/en-us/hololens Penn Image-Guided Interventions (PIGI) Lab: https://www.med.upenn.edu/pigilab/

$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Asthma 1:29, COPD 7:50, Pulmonary function tests 13:03, Interstitial lung disease 16:23, Pneumonia 21:09, Tuberculosis 27:55, Fungal lung infections 32:03, Bronchiolitis 34:14, Acute bronchitis 35:14, Stridor 36:06, Croup 36:57, Foreign body aspiration 37:30, Epiglottits 39:38, Anaphylaxis 40:12, Angioedema 41:40, Nasopharyngeal obstructions 42:39, Lung cancer 45:05, Pulmonary embolism 47:43, Pneumothorax 51:00, Pleural effusion 54:09, Congestive heart failure and pulmonary edema 57:20, Non-cardiogenic pulmonary edema 1:01:38, Pulmonary hypertension 1:05:07, Honorable mentions 1:08:04, Practice questions, 01:10:42

Today the PulmPEEPs are joined by two amazing educators as we start off our Top Consult series on Pleural Disease. Join us today as we go through cases to learn a systematic approach for evaluation and management of pleural effusions. … Continue reading →

2.19 Pleural Effusions: Transudate vs Exudate Pulmonary system review for the USMLE Step 1 Exam Pleural effusion is an abnormal accumulation of fluid in the pleural cavity. Pleural effusions can be characterized as either exudative or transudative based on the content of the extra fluid. Exudative effusions have high protein and lactate dehydrogenase content, while transudative effusions have low protein and lactate dehydrogenase content. Pleural exudates are commonly caused by lung infections, lung cancer, and inflammatory diseases. Pleural transudates are caused by increased hydrostatic pressures or decreased oncotic pressure within the lung capillaries that force fluid into the pleural cavity. Transudative effusions are not caused by inflammation, so lactate dehydrogenase content is not expected to be high. Proteins are too big to move between cells, so transudative effusions have low protein content.

On this episode of the PTA Elevation Podcast, host Briana Drapp, SPT, PTA, CSCS goes over the important things to know about Pleural Effusion when studying for the NPTE. At the end of this episode, Briana provides and reviews a sample question that helps students get a feel for how this subject will be asked on the NPTE - PTA. Tune in to learn more! Website: https://www.ptaelevation.com/ Join our FB group for FREE resources to help you study for the exam! https://www.facebook.com/groups/382310196801103/ If you're interested in our prep course, check it out here: https://ptaelevation.com/the-600-plus-system Follow us on our other platforms! https://www.ptaelevation.com/linktree We look forward to serving you!

Episode 49 - UK Based Approach To Pleural Service And Pleuroscopy - Eihab Bedawi (1) by AABIP

Dr. Van Holden is an Associate Professor and Program Director of the Pulmonary and Critical Care Medicine Fellowship Program at the University of Maryland, School of Medicine. She presents a lecture entitled "Pleural Disorders" as part of the DC5 lecture series.

Discussing pleural effusions in the critically ill, including how and when to drain them, methods of drainage, interpreting laboratory studies, and managing complications, with Dr. Emily Fridenmaker (@emily_fri), pulmonologist and intensivist at Charleston Area Medical Center in West Virginia. Continuing education for this episode CME credit provided courtesy of Academic CME. To claim your CME … Continue reading "Episode 52: Pleural effusions in the ICU with Emily Fridenmaker"

In this episode, we review the high-yield topic of Pleural Effusion from the Respiratory section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

About this episode In this week's question dissection, Swati and Dr. Maxwell Cooper review the case of a 56 year old male who is currently receiving treatment for lung cancer who presents to the ED with worsening shortness of breath. A chest x-ray reveals a known left lower lobe mass and a new large left pleural effusion. Links for this episode DaVinci Academy on YouTube DaVinci Academy website - Discount code ITB20 for 20% off at checkout! #DaVinciCases on Spotify #DaVinciCases on Apple Podcasts The DaVinci Hour on Spotify The DaVinci Hour on Apple Podcasts ITB Tutoring Study on the go for free! Download the Audio QBank by InsideTheBoards for free on iOS or Android. If you want to upgrade, you can save money on a premium subscription by customizing your plan until your test date on our website! All of our podcasts: The InsideTheBoards Podcast The InsideTheBoards Study Smarter Podcast Crush Step 1 Step 2 Secrets Physiology by Physeo Step 1 Success Stories Beyond the Pearls The Dr. Raj Podcast The Health Beat Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan and Erin McCue. Executive Producer: Patrick C. Beeman, MD Legal Stuff InsideTheBoards is not affiliated with the NBME, USMLE, COMLEX, or any professional licensing body. InsideTheBoards and its partners fully adhere to the policies on irregular conduct outlined by the aforementioned credentialing bodies. The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Chapter 26 of Sloterdijk's 'Critique of Cynical Reason', Weimar Double Decisions, or: Matter-of-Factness unto Death

Welcome to our 40th episode! Here we discuss the intricacies of pleural effusions, including their various causes (and of course, Light's criteria!). Enjoy!

ONS member Roberta Kaplow, RN, PhD, CCRN, AOCNS®, clinical nurse specialist at Emory University Hospital in Atlanta, GA, and member of the Metro Atlanta ONS Chapter, talks with Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, about the latest nursing management and prevention strategies for malignant pleural effusion. This episode is a part of a series about oncologic emergencies; the previous episodes are linked in the episode notes. You can also earn free NCPD contact hours by completing the evaluation linked in the episode notes.    Music Credit: "Fireflies and Stardust" by Kevin MacLeod   Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by May 13, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Episode Notes  Check out these resources from today's episode:  Complete this evaluation for free NCPD.  Previous Oncology Nursing Podcast episodes on oncologic emergencies ONS book: Understanding and Managing Oncologic Emergencies: A Resource for Nurses (third edition) Clinical Journal of Oncology Nursing articles about malignant pleural effusion American Thoracic Society's malignant pleural effusion patient education sheet Pleural catheter patient education video (from manufacturer) Pleural catheter provider information (from manufacturer)  The podcast conversations represent the guest's ideas and opinions and not necessarily those of ONS. Mention of specific products and opinions related to those products does not indicate endorsement by ONS.   To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. 

Pedro, Fred e Amyr discutem sobre a punção do líquido pleural e os exames de análise do líquido pleural. Referências em breve!

Meg speaks with Dr. Luna Gargani, Cardiologist and Researcher at the University of Pisa in Pisa, Italy.As an advocate and pioneer of point-of-care lung ultrasound, Luna has played a key role in bringing this technology full-circle. Meg and Luna talk about the dramatic impact one key mentor made in her career, why, despite much resistance, Luna was confident a novel technology she was researching would one day become widely accepted, and the value of carefully choosing what to focus one's research on especially if, like Luna, you are naturally curious and passionate about making an impact in a wide variety of challenges in healthcare.Sostenitrice e pioniera dell'ecografia polmonare point-of-care, la dott.ssa Gargani ha avuto l'opportunità di vedere questa tecnologia svilupparsi dagli esordi più incerti fino a prosperare. Meg e Luna parlano non solo del ruolo cruciale che un mentore ha avuto nello sviluppo personale e professionale della dottoressa, ma anche del motivo per cui, nonostante le molte resistenze, Luna era sicura che quella nuova tecnologia che stava investigando sarebbe stata un giorno ampiamente accettata. Infine, si confrontano sull'importanza di scegliere scrupolosamente l'oggetto della propria ricerca soprattutto se, come Luna, si e' curiosi di natura ed intenzionati ad avere un impatto concreto nel vasto spettro di sfide che si profilano nel settore sanitario.Luna Gargani, MD is a Cardiologist and Researcher at the University of Pisa in Pisa, Italy. At the time of this recording, she had been Senior Researcher for the Institute of Clinical Physiology of the National Research Council for 18 years.Dr. Gargani's research focuses on cardiovascular imaging and point-of-care echocardiography. She is a pioneer in lung ultrasound, a recognized expert on the topic and was a member of the committee that wrote the first set of international, evidence-based recommendations for point-of-care lung ultrasound. Further Reading: University of Pisa Clinical Physiology Institute CNR - PisaHandsonechoFirst International Consensus Conference Expert Committee on Pleural and Lung UltrasoundAmerican Heart Association Study by Dr. Sarah Zaman, Elizabeth Shaw and Sonya Burgess,in Australia Originally published 19 Feb 2019Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study Epub 2021 Mar Eugenio Picano Episode CreditsThe Game-Changing Women of Healthcare is a production of The Krinsky Company. Hosted by Meg Escobosa. Produced, edited, engineered, and mixed by Calvin Marty. Theme music composed and performed by Calvin Marty. Intro and outro voiced by John Parsons. ©2022 The Krinsky Company

In Part II of our Lung Biopsy Series Dr. Fred Lee and Dr. Christopher Beck discuss Pleural and Parenchymal Blood Patching to prevent Pneumothorax, including results of the recent JVIR article from Sept 2021. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/0lTQ87 --- SHOW NOTES In this episode, Dr. Fred Lee and our host Dr. Chris Beck discuss the use of parenchymal and pleural blood patches to reduce the rate of lung biopsy re-interventions. First, Dr. Lee describes why he has incorporated parenchymal blood patching at the end of most biopsies, noting that it is a straightforward procedure that only adds on a few extra minutes to the overall biopsy, and it can reduce the rate of re-intervention. Both doctors agree that minimizing the need for chest tubes can greatly improve the patient experience. Pleural blood patches are used as a salvage technique in the event of a pneumothorax. Dr. Lee walks through his process of re-inflating the lung, finishing the biopsy, and using a three-way stopcock to inject blood onto the pleural surface and along the needle track. He notes that there are other valid ways of treating intraprocedural pneumothoraces (saline, fibrin plug, etc); however, he prefers the pleural blood patch because of its liquid-to-solid clotting transition, minimal time, minimal cost, and relatively low risk. Throughout this episode, we cite data from Dr. Lee's previous publications, which are cited below. --- RESOURCES Percutaneous Lung Biopsy with Pleural and Parenchymal Blood Patching: Results and Complications from 1,112 Core Biopsies: https://www.jvir.org/article/S1051-0443(21)01202-1/fulltext CT-Guided Lung Biopsies: Pleural Blood Patching Reduces the Rate of Chest Tube Placement for Postbiopsy Pneumothorax: www.ajronline.org/doi/full/10.2214/AJR.10.6324 Pulmonary Intraparenchymal Blood Patching Decreases the Rate of Pneumothorax-Related Complications following Percutaneous CT–Guided Needle Biopsy: www.jvir.org/article/S1051-0443…6)32178-9/fulltext

We start off Part 1 of a 2 part series with Dr. Fred Lee discussing Percutaneous Lung Biopsy Technique, with tips and tricks to help your daily practice. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/QD39HM --- SHOW NOTES In this episode, Dr. Fred Lee and our host Dr. Chris Beck discuss tips for achieving safe and successful percutaneous lung biopsies. They start by discussing the increasing popularity of core biopsy (as opposed to fine needle aspiration), since an adequate amount of specimen is needed for genetic testing and personalized medicine. Dr. Lee emphasizes that knowing the goals of lung biopsy for each individual patient helps him decide how much specimen to collect and how the specimen should be handled. Next, Dr. Lee walks through his lung biopsy technique. He outlines the difference between conventional CT and CT with fluoroscopy. While CT with fluoroscopy can be more efficient, it poses radiation risk to the patient and the physician. To minimize radiation risks, he advises IRs to intermittently tap the foot pedal and stand lateral to the CT scanner. The doctors also discuss some of the trickiest lung regions to biopsy and ways to avoid pneumothorax. Finally, Dr. Lee comments on the choice between percutaneous lung biopsies and electromagnetic navigation bronchoscopy, noting that each procedure has different advantages and risks. He encourages interventional radiologists and interventional pulmonologists to explore these options and take evidence-based approaches. Throughout this episode, we cite data from Dr. Lee's previous publications, which are cited below. --- RESOURCES Percutaneous Lung Biopsy with Pleural and Parenchymal Blood Patching: Results and Complications from 1,112 Core Biopsies: https://www.jvir.org/article/S1051-0443(21)01202-1/fulltext

In this episode, we review the high-yield topic of Pleural Effusion from the Pediatrics section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets